Recomendados
Recomendados
Más contenido relacionado
Similar a Ardis final
Similar a Ardis final (20)
Más de Stanford University
Más de Stanford University (20)
Último
Último (20)
Ardis final
- 1. Advanced Retinal Diagnostic Imaging Services Alex Etlin, PhD Vickie Zhang, PhD(c) Brandon Lujan, MD Total Interviews: 101 Luke Lee, MBA
- 2. Age-related Macular Degeneration (AMD)
- 3. Age-related Macular Degeneration (AMD) Advanced Form
- 4. Age-related Macular Degeneration (AMD) Early Form Advanced Form
- 5. Age-related Macular Degeneration (AMD) Early Form Advanced Form
- 6. Total Available Market $12 billion Target Market $120 million
- 9. •Asymptomatic adults don’t care to be imaged •Most AMD patients would like to be monitored more frequently
- 11. Clinical evidence showing frequent monitoring results in better patient outcomes. Clinicians don’t think they should pay for our service.
- 12. To get and keep patients, “you have to provide easy access and financial support so patients don’t have to pay.” Then patients would want to show up
- 13. We learned: Customer segments What do they want? Asymptomatic individuals Patients Would like to be monitored frequently Prefer easy access to care Some are willing to pay Clinicians Want to see clinical evidence Do not want to pay Who should be our payers? Insurance companies? Pharma companies?
- 14. •Clinical evidence that frequent monitoring leads to better patient outcomes •Frequent monitoring would reduce overall healthcare costs! Validation: Early detection of disease progression => decrease cost of treatments CLINICAL TRIAL
- 15. What does industry say?
- 16. Industry: Overwhelmed by Data “We Need insight from existing clinical data” To better design what is coming next: Who to include? What endpoints?
- 18. Where do we go from here? 1. Already submitted three analysis proposals 2. How can we build value using other’s data? 3. Perform our own trial and protect insights
- 19. Pilot Clinical Data: Frequent Monitoring Matters San Francisco VA Medical Center
Notas del editor
- We interviewed over 30 asymptomatic older adults & AMD patients. We found out asymptomatic adults don’t care to be imaged, while AMD patients feel they are not being adequately monitored, and would like to be monitored more often.(25 sec)
- We interview about 40 clinicians (2sec)
- We learn that to convince clinicians to refer patients to our service, we first must demonstrate that frequent monitoring would result in better patient outcomes. They want to see clinical evidence in the form of publications. Also, we found out clinicians can be users, but they would not want to pay.(25 sec)
- Dr. Lillie Mosddegh said she would refer patients to us if we can show clinical evidence. She also taught us how to get and keep patients. We have to provide easy access since AMD patients are older and often not independent. Also, we should provide financial support to they don’t have to pay out of pocket. Once we cover these 2 key issues, we should be able to get high compliance rate.(27sec)
- Base on our interviews, we crossed out asymptomatic individuals. We learned patients do have the needs to be monitored more often, and easy access to get to care. However, only some are willing to pay out of pocket. Clinicians would be on board once they see clinical evidence that our service can improve patient outcomes. However, they don’t think they should be paying for it. To figure out who should be our payers, we turned to insurance companies and pharma companies. (27sec)
- We then spoke to insurance reimbursement experts. And found in order to convince insurance companies to cover our service, we must first provide evidence that frequent monitoring lead to better patient outcomes, just like clinicians. Second, we have to show our service reduces overall healthcare cost. Because after all, they are in a business. We believe we our service does reduce healthcare costs. Because cost of treatments would decrease with early detection of disease progression. And treatments in the form of injections can be very expensive for advanced AMD. Of course, we have to conduct a clinical trial to demonstrate that.(~3 min)